BLUE BELL, PA - (ACCESSWIRE - November 11, 2013) - Inovio Pharmaceuticals, Inc. (INO) will host a live webcast to discuss the results of the third quarter 2013, to be held Tuesday, November 12, 2013 at 8:30 a.m. Eastern Time.
You can listen to the event online at http://www.investorcalendar.com/IC/CEPage.asp?ID=171876.
If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=171876 or http://www.investorcalendar.com/, as well as via the Inovio Pharmaceuticals web site (http://www.inovio.com/).
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at http://www.inovio.com/
SOURCE: ACCESSWIRE